Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PharmaMar will retain exclusive production rights for Yondelis®(trabectedin), which will be sold to Key Oncologics for its clinical and commercial use in South Africa, Namibia and Botswana.
Lead Product(s): Trabectedin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: PharmaMar
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 19, 2020